Xiuning Le, MD, PhD, discusses data from the HARMONi-2 trial of ivonescimab vs pembrolizumab in PD-L1–positive NSCLC.
Bridging the Gaps With Bispecific Antibody Therapy in NSCLC
Jonathan Wesley Riess, MD, MS, discusses data from the phase 3 HARMONi-2 trial evaluating ivonescimab vs pembrolizumab in advanced NSCLC.
Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5